Navigation Links
Study looks at safety, effectiveness of generics for treating depression
Date:11/4/2013

Researchers at Washington University School of Medicine in St. Louis are studying the quality, effectiveness and safety of generic drugs used to treat depression.

The research is supported by the U.S. Food and Drug Administration (FDA) and is the only study of its kind funded by the agency. The study will determine whether brand-name 300 mg bupropion hydrochloride (HCl) extended-release (ER) tablets sold commercially as Wellbutrin XL and the various generic versions of bupropion HCl ER tablets work the same in the body and deliver the same therapeutic benefits.

The principal investigator is Evan D. Kharasch, MD, PhD, the Russell D. and Mary B. Shelden Professor of Anesthesiology and an expert in clinical pharmacology, drug metabolism, drug interactions, mechanisms of drug toxicity and pharmacogenetics, a clinical pursuit that focuses on understanding the ways that individuals can respond to the same drug differently.

"Since generic versions of extended-release bupropion HCl were introduced, there have been some reports that they may not be as effective as the brand-name drug and may be associated with adverse events," Kharasch said. "The first time a 300 mg generic version of this drug was tested, there were significant differences in drug concentrations in the blood compared with what was seen with the brand-name drug, Wellbutrin XL, and that generic formulation eventually was taken off the market. Now, we're going to study several generics to evaluate their blood concentrations in patients, how effective they are, and whether they are associated with side effects or with relapse. This study will go beyond the tests that have been conducted previously."

Kharasch, an anesthesiologist at Barnes-Jewish Hospital and also vice chancellor for research at Washington University, is collaborating with Eric Lenze, MD, professor of psychiatry. They will study blood samples from patients with depression to learn how much of the generic and brand-name drugs get into the bloodstream and how long the medications remain in the system.

And they'll compare how patients say they feel when taking brand-name versus generic versions of the same drug. Lenze, an expert on treatment studies for depression, developed innovative approaches for patient participation and monitoring in this study. Patients will report their symptoms daily using a cell phone-based program, which will be easier and more accurate than less frequent in-person assessments, the usual method for monitoring symptoms.

The Washington University researchers also will collaborate with national pharmacy benefit manager Express Scripts to look at outcomes of people taking the various formulations of the drug.

"This project promises to develop a new model for determining drug safety and effectiveness using data from a pharmacy benefit manager on a massive scale to actively monitor patients taking the drug," Kharasch said. "This model has the potential to help us detect potential problems and to intervene much earlier than currently possible. We very much value the opportunity to collaborate with Express Scripts and have access to its wealth of data on this project to improve patient safety."

Express Scripts manages the pharmacy benefit for tens of millions of Americans, processing more than 1 billion prescriptions each year.

Kharasch believes the three-year, $2.8 million dollar grant will help determine whether this particular generic drug works as well as the brand-name version. It also should contribute to the understanding of how an individual's DNA can influence whether a particular medication is effective.

"Another goal of the research is to study the pharmacogenetics of bupropion that is, how patients' genetic makeup affects their blood concentrations and response to the drug," Kharasch said. "We also will learn much more about the genetic variability of one of the major enzymes in the liver that is responsible for eliminating drugs from the body, and how that influences clinical outcomes."


'/>"/>

Contact: Jim Dryden
jdryden@wustl.edu
314-286-0110
Washington University School of Medicine
Source:Eurekalert  

Related medicine news :

1. Study Suggests Vaccine May Help Kids With Brain Cancer
2. Study reveals how cancer drug causes diabetic-like state
3. Coffee Drinking in Pregnancy Wont Lead to Sleepless Baby: Study
4. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
5. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
6. No Added Cancer Risk From Hip Replacement Materials: Study
7. Reported Decline in U.S. Pneumonia Deaths May Be False: Study
8. Early Study Finds Some Promise for Lung Cancer Vaccine
9. Narcissists Often Ace Job Interviews, Study Finds
10. Sexual objectification of female artists in music videos exists regardless of race, MU study finds
11. Soy may alleviate hot flashes in menopause, large-scale study finds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study looks at safety, effectiveness of generics for treating depression
(Date:3/27/2017)... ... March 27, 2017 , ... M&S ... Certificate of Conformity for the Smart System® 20/20. CE Certification builds upon M&S's ... standards and specifications such as ANSI, ISO and proven test methods used in ...
(Date:3/27/2017)... PA (PRWEB) , ... March 27, 2017 , ... ... business simulation -centric training, today announced the launch of a new research ... strategy, having the skills needed to execute that strategy, and the actual success ...
(Date:3/27/2017)... ... March 27, 2017 , ... According to the American Cancer ... stages, is more than 95%. Once the cancer spreads to other organs, bones, or ... find out how to avoid this latter group, tune in to Lifestyle Magazine ...
(Date:3/27/2017)... Texas (PRWEB) , ... March 27, 2017 , ... ... at the GTEC Orange facility from 8:00am-10:00am on Monday, April 3rd to commemorate ... and will be an opportunity for area-residents to celebrate two great years while ...
(Date:3/25/2017)... PA (PRWEB) , ... March 25, 2017 , ... Getting ... as a public relations partner. , All through the year, Garden Media aims ... press releases, working with key influencers and pitching client’s key messages to ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... , March 27, 2017  ImMAGE Biotherapeutics (OTCMKTS: ... immunotherapy successfully passed early toxicology and efficacy studies. The ... to target a specific protein, MAGE A, in an ... breast cancer. After 4 weeks of ... to show very little toxicity in a full toxicology ...
(Date:3/27/2017)... , March 27, 2017  Sanderling Ventures, portfolio ... Ethicon, a division of Johnson & Johnson. Torax manufactures ... the treatment of gastro-esophageal reflux disease (GERD). The ... (MSA) technology and the procedure is currently available ... Torax Medical was founded by Sanderling Ventures, ...
(Date:3/27/2017)... TEL AVIV, Israel , March 27, 2017 ... focused on oncology and immunology, announced today that AGI-134, an ... recently announced acquisition of Agalimmune Ltd., will be featured at ... Meeting in Washington, DC to ... ...
Breaking Medicine Technology: